IGNITE II, or Implementing GeNomics In pracTiCe, is an NIH-funded network dedicated to supporting the implementation of genomics in healthcare.
The network is comprised of five research sites, a coordinating center, a steering committee, and working groups. The National Human Genome Research Institute and a data safety and monitoring board provide oversight for all network activity and is intricately involved in all aspects of the IGNITE II Network design and operation.
In order to provide the evidence that genomic medicine will improve patient outcomes, the IGNITE Network will conduct 2 – 3 large, network-wide genomic medicine pragmatic clinical trials (PCTs), which will allow for bigger, more efficient clinical trials and help researchers and clinicians understand what to expect in real-world clinical settings. These include GUARDD-US and ADOPT-PGx.
The IGNITE Network also disseminates the methods and best practices its members develop in order to advance the implementation of genomics in healthcare. One outlet for public distribution is the SPARK Toolbox, which provides genomic medicine resources for clinicians and researchers. Another will be the creation of the genomic medicine knowledge base where ideas can be shared so that everyone can begin to use this in practice, whether in community clinics or academic medical centers.
What are Pragmatic Clinical Trials?
Pragmatic Clinical Trials are "designed for the primary purpose of informing decision-makers regarding the comparative balance of benefits, burdens and risks of a biomedical or behvavioral health intervention at the individual or population level."
Source: Califf RM, Sugarman J. 2015. Exploring the ethical and regulatory issues in pragmatic clinical trials. Clin Trials. 12:436–441. doi:10.1177/1740774515598334.
A Depression and Opioid Pragmatic Trial in Pharmacogenomics
Pain and depression are conditions that impact substantial proportions of the US population. Finding safe and effective drug therapies for both conditions is challenging. ADOPT-PGx is a pragmatic clinical trial that enrolls patients into three PGx-guided therapy scenarios: acute post-surgical pain, chronic pain, and depression. For each scenario, participants will be randomized to genotype-guided drug therapy versus usual approaches to drug therapy selection (hereafter referred to as usual care). Changes in patient-reported outcomes representing pain and depression control using standard PROMIS scales define the primary endpoints. Secondary analyses include safety endpoints, changes in overall well-being, and economic impact represented by differences in healthcare utilization.
Genetic testing to Understand Renal Disease Disparities across the U.S.
Lead Site: Mount Sinai
GUARDD-US is a pragmatic clinical trial that aims to determine the effect of returning APOL1 genetic risk information to hypertensive African ancestry patients and their primary care providers on systolic blood pressure (SBP). The primary outcome is SBP at three months comparing patients with high-risk APOL1 variants (positives) vs. no high-risk variants (negatives). The co-primary outcome is three-month SBP in positives vs. those receiving delayed testing. Secondary outcomes include renal disease testing, and psycho-behavioral factors. We will re-randomize APOL1 negative patients to a genotype-guided approach to anti-hypertensive therapy versus usual care and compare three-month SBP.
Events and News
NHGRI publishes overview about IGNITE
Three IGNITE PIs presented at Precision Medicine Conference
Julie Johnson, PharmD, Carol Horowitz, M.D., M.P.H., and Josh Denny, M.D., were three of the presenters at the University of Florida Precision Medicine Conference, held March 6-7, 2019 in Orlando, Florida. This conference brings together clinicians, researchers and other thought leaders from medicine and pharmacy to receive cutting edge guidance from professionals with experience implementing genomic medicine and pharmacogenomics in a variety of settings.
PHASeR: A collaboration in PGx to help veterans
There are about 15 million cancer survivors in the United States; about 400,000 of them are also veterans in the Veterans Affairs (VA) system. As more people survive cancer, their medication needs go beyond their cancer treatment. For veterans, VA physicians hope to bring more personalization to cancer survivorship plans for patients with pharmacogenetic testing. Read more on CAGPM website
What is the SPARK TOOLBOX?
The SPARK Toolbox reflects a collection of expert consensus regarding special considerations, standard approaches, and best practices in the design, conduct, and reporting of Genomic Medicine. Given the rapid pace of change in this field, this Toolbox will continue to be added to and updated.
SPECIALIZE IN GENOMIC MEDICINE
IGNITE II is comprised of five research sites that help promote the mission of the network through support from a coordinating center, working groups, affiliate members, and an external scientific panel. Each network site provides educational opportunities that provide an opportunity to learn more about genomics and how to best implement into healthcare.